E!1512 ACTaNe
| Reference number | |
| Coordinator | Karolinska Institutet - Karolinska Institutet Inst f fysiologi & farmakologi |
| Funding from Vinnova | SEK 2 921 000 |
| Project duration | January 2023 - January 2026 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
The project largely achieved its objectives and generated new knowledge about NP137 and the mechanisms underlying persistent joint pain. We showed that netrin-1 is expressed in osteoclasts and synovial fibroblasts and increases during joint inflammation. Furthermore, blocking netrin-1 with the antibody NP137 can reduce pain-like behavior in mice and synovial hyperinnervation. These findings provide a foundation for the further development of new treatments for musculoskeletal pain.
Expected long term effects
The project has increased understanding of the mechanisms underlying persistent musculoskeletal pain in inflammatory joint diseases. The discovery of netrin-1 in synovial fibroblasts and its link to increased nerve density in the synovium and pain opens new opportunities to develop treatments targeting pathological nerve growth, for example through the netrin-1–blocking antibody NP137. The project has also strengthened collaborations between academia, clinical researchers, and industry.
Approach and implementation
The project was largely carried out as planned, and most activities followed the original timeline. Some delays occurred due to method optimization, personnel changes, and unexpected experimental results, which required adjustments to the workflow. Collaboration within the consortium worked well and was characterized by regular communication and knowledge exchange between academia and industry, which contributed positively to the project’s implementation.